JP2893710B2 - Leukocyte separation filter - Google Patents
Leukocyte separation filterInfo
- Publication number
- JP2893710B2 JP2893710B2 JP1110683A JP11068389A JP2893710B2 JP 2893710 B2 JP2893710 B2 JP 2893710B2 JP 1110683 A JP1110683 A JP 1110683A JP 11068389 A JP11068389 A JP 11068389A JP 2893710 B2 JP2893710 B2 JP 2893710B2
- Authority
- JP
- Japan
- Prior art keywords
- fiber
- filter
- diameter
- blood
- average
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000265 leukocyte Anatomy 0.000 title claims description 40
- 238000000926 separation method Methods 0.000 title claims description 4
- 239000000835 fiber Substances 0.000 claims description 37
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 230000035699 permeability Effects 0.000 claims description 13
- 239000004745 nonwoven fabric Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 10
- 229920001410 Microfiber Polymers 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 239000003658 microfiber Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
- B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
- B01D39/1607—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous
- B01D39/1623—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous of synthetic origin
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- External Artificial Organs (AREA)
Description
【発明の詳細な説明】 （産業上の利用分野） 本発明は、血液より白血球を分離するフィルターさら
に詳しくは、リウマチ等の自己免疫疾患患者の血液から
血小板は透過し、効率的かつ安全に白血球のみを選択分
離除去するためのフィルターに関する。Description: FIELD OF THE INVENTION The present invention relates to a filter for separating leukocytes from blood. More specifically, the present invention relates to a method for efficiently and safely transmitting platelets from blood of patients with autoimmune diseases such as rheumatism. It relates to a filter for selectively separating and removing only
（従来の技術） リウマチ等の自己免疫疾患患者の血液からリンパ球を
含む白血球を除去することにより臨床症状が改善するこ
とが報告されている。（例えばTsuda,H.,Yokoyama,M.,e
tal:New Trial oflymphocytapheresis combined with double−filtration by using of “Sepacell"in the t
reatment of rhenmatoid orthritis Theropeutic Plcsm
apheresis V 369−372,（1986）） 血液から白血球を除去する方法はいくつか知られてい
るが治療に用いられるのは遠心分離法とフィルターによ
る吸着法（例えば特開昭62−243561）である。遠心分離
法は、大量処理が可能であるが、装置が高価であるこ
と、白血球の除去率が低いこと、血小板赤血球も白血球
と共にかなりの量が除去されてしまう等の問題がある。(Prior Art) It has been reported that clinical symptoms are improved by removing leukocytes including lymphocytes from the blood of patients with autoimmune diseases such as rheumatism. (For example, Tsuda, H., Yokoyama, M., e
tal: New Trial oflymphocytapheresis combined with double-filtration by using of “Sepacell” in the t
reatment of rhenmatoid orthritis Theropeutic Plcsm
apheresis V 369-372, (1986)) There are several known methods for removing leukocytes from blood, but the treatment used is a centrifugation method and an adsorption method using a filter (for example, JP-A-62-243561). . The centrifugal separation method can perform a large amount of processing, but has problems such as an expensive apparatus, a low removal rate of white blood cells, and a considerable amount of platelet red blood cells and white blood cells are removed.
一方フィルターによる吸着法は、白血球を効率よく除
去でき、装置も小型で操作も容易であるが、血小板も同
時に大量に除去してしまう。On the other hand, the adsorption method using a filter can efficiently remove leukocytes, and the device is small and easy to operate, but also removes a large amount of platelets at the same time.
一方近年になって不織布フィルターを親水性物質でコ
ーティングを施し、血小板透過性を向上させた製品が報
告されている。しかしながらこれらに血液を流すと血液
中の補体成分が活性化するとともに、白血球が一過的に
減少することが報告されている。On the other hand, recently, a product in which a nonwoven fabric filter is coated with a hydrophilic substance to improve platelet permeability has been reported. However, it has been reported that when blood is supplied to these cells, complement components in the blood are activated and leukocytes are transiently reduced.
（発明が解決しようとする課題） 従来までの不織布フィルターによる血液中から白血球
除去を行う方法では、血小板が大量に除去されてしま
う。あるいは親水性物質のコーティングにより血小板透
過性を向上させると、血液中の補体成分が活性化し、白
血球が一過的に減少するといった課題がある。(Problems to be Solved by the Invention) In a conventional method of removing leukocytes from blood using a nonwoven fabric filter, a large amount of platelets is removed. Alternatively, when the platelet permeability is improved by coating with a hydrophilic substance, there is a problem that complement components in blood are activated and leukocytes are temporarily reduced.
本発明は、血液から血小板を大部分透過し、かつ効率
的かつ安全に白血球を除去するための装置及び方法を提
供することを目的とする。An object of the present invention is to provide an apparatus and a method for efficiently and safely removing leukocytes, which largely allow platelets to pass from blood.
（課題を解決するための手段） 従来までの不織布による白血球除去フィルターは、繊
維直径が１〜２μｍであり、白血球除去効率は高いが同
時に血小板も除去してしまう。そこで本発明者らは、不
織布フィルター繊維径と白血球および血小板除去性の関
係について鋭意検討を行った結果、繊維径繊維間隙、フ
ィルター表面積、処理温度を調整することにより、白血
球と血小板の選択性を制御しうることを見い出した。す
なわち、従来までの不織布による白血球除去フィルター
の繊維よりも太い繊維径を有するフィルターを用い、体
温付近の処理温度条件で、かつ白血球の除去率が98％以
下のとき、おどろくべきことに血小板がほぼ100％透過
することを見い出し、本発明に至った。(Means for Solving the Problems) A leukocyte removal filter using a conventional nonwoven fabric has a fiber diameter of 1 to 2 μm and has high leukocyte removal efficiency, but also removes platelets at the same time. Therefore, the present inventors have conducted intensive studies on the relationship between the nonwoven fabric filter fiber diameter and the leukocyte and platelet removal properties.As a result, by adjusting the fiber diameter fiber gap, the filter surface area, and the treatment temperature, the selectivity between leukocytes and platelets was improved. I found something that I could control. That is, when using a filter having a fiber diameter larger than the fiber of the leukocyte removal filter using a conventional nonwoven fabric, at a processing temperature near body temperature, and when the leukocyte removal rate is 98% or less, surprisingly, platelets almost disappear. It has been found that 100% transmission is achieved, and the present invention has been achieved.
すなわち、リウマチ等の自己免疫疾患患者の血液より
白血球を除去する療法において、治療効果は、白血球の
除去量に依存すると考えられ、フィルターでの除去率を
約100％とする必要性はなく、70〜80％で充分である。That is, in the therapy for removing leukocytes from the blood of a patient with an autoimmune disease such as rheumatism, the therapeutic effect is considered to depend on the amount of leukocytes removed, and it is not necessary to set the removal rate with a filter to about 100%. ~ 80% is sufficient.
すなわち本発明は、白血球の除去率が70〜98％の範囲
であり、かつ血小板透過率がほぼ100％、低補体活性で
ある効率、安全性の高い白血球除去装置および方法に関
するものである。That is, the present invention relates to a highly efficient and safe leukocyte removal apparatus and method having a leukocyte removal rate in the range of 70 to 98%, a platelet permeability of almost 100%, low complement activity, and high safety.
すなわち、本発明のフィルターは、繊維の平均直径が
3.0〜8.0μｍであり、フィルター繊維の表面積が処理血
液１当たり2.0〜10.0m2であって、次式で定義される
繊維間隙の平均円相当直径が16.0〜35.0μｍになるよう
に充填された白血球除去率が70〜98％、血小板透過率が
90％以上である白血球分離フィルターであることを特徴
とする。That is, the filter of the present invention has an average fiber diameter.
3.0 to 8.0 μm, and the filter fiber was packed so that the surface area of the filter fiber was 2.0 to 10.0 m 2 per treated blood, and the average circle equivalent diameter of the fiber gap defined by the following formula was 16.0 to 35.0 μm. Leukocyte removal rate 70-98%, platelet permeability
The leukocyte separation filter is 90% or more.
DH：繊維間隙の平均円相当直径（μｍ） γ :繊維の平均直径（μｍ） ρ :繊維の密度（g/cm3） γm:フィルターの嵩密度（g/cm3） 繊維径を3.0μｍ以上、繊維間隙の平均円相当直径を1
6.0μｍ以上とすることで白血球除去率と血小板透過率
を高めることができる。一方繊維径を8.0μｍ以上とす
るとフィルターは嵩高になってしまい装置が大きくな
り、平均円相当直径30.0μｍ以上とすると白血球の除去
率が低下してしまい好ましくない。 D H : average circle equivalent diameter of fiber gap (μm) γ: average diameter of fiber (μm) ρ: density of fiber (g / cm 3 ) γm: bulk density of filter (g / cm 3 ) Fiber diameter is 3.0 μm Above, the average circle equivalent diameter of the fiber gap is 1
By setting the thickness to 6.0 μm or more, the leukocyte removal rate and platelet permeability can be increased. On the other hand, if the fiber diameter is 8.0 μm or more, the filter becomes bulky and the device becomes large, and if the average circle equivalent diameter is 30.0 μm or more, the leukocyte removal rate decreases, which is not preferable.
また、本発明の装置においては、フィルター繊維の表
面積が処理血液１当り2.0〜10.0m2であることを特徴
とする。Further, the apparatus of the present invention is characterized in that the surface area of the filter fiber is 2.0 to 10.0 m 2 per treated blood.
繊維表面積が処理血液１当り2.0m2以下とすると、
白血球を吸着する面積が狭くなるため、白血球を吸着し
きれなくなる10m2以上とすると、吸着面積が大きくなり
すぎ、血小板吸着量が増加するとともにフィルターが嵩
高になってしまい好ましくない。If the fiber surface area is 2.0 m 2 or less per processed blood,
Since the area for adsorbing leukocytes is reduced, if the area is not less than 10 m 2, which cannot adsorb leukocytes, the adsorbing area becomes too large, the platelet adsorption amount increases, and the filter becomes bulky, which is not preferable.
また、本フィルターの使用方法は、血液の処理温度を
20℃以上とすることを特徴とする。処理温度を20℃以上
とすることではじめて白血球と血小板の選択性が発現す
る。20℃以下では血小板の非特異的な吸着が起こり好ま
しくない。もちろん42℃以上では熱により血液が変性す
るため好ましくない。The use of this filter depends on the processing temperature of blood.
It is characterized by being at least 20 ° C. Only when the treatment temperature is 20 ° C. or higher, the selectivity of leukocytes and platelets is developed. Below 20 ° C, non-specific adsorption of platelets occurs, which is not preferable. Of course, a temperature of 42 ° C. or higher is not preferable because blood is denatured by heat.
本発明のフィルター素材は必ずしも限定されるもので
はないが、良好な白血球除去能を有し、補体活性が少な
く生体適合性に優れる疎水性のポリプロピレンやポリエ
ステル等が望ましい。フィルターの形態としては不織布
状が望ましい。この様な素材から本発明のフィルターに
用い得る極細繊維不織布を得る方法としては、メルトブ
ロー紡糸法が特に好ましい。Although the filter material of the present invention is not necessarily limited, hydrophobic polypropylene or polyester having good leukocyte removing ability, having a low complement activity and excellent biocompatibility is desirable. As a form of the filter, a non-woven fabric is desirable. As a method for obtaining a microfiber nonwoven fabric usable for the filter of the present invention from such a material, a melt blow spinning method is particularly preferred.
以下実施例により、本発明の効果ならびにより詳細な
説明を加える。The effects of the present invention and a more detailed description will be given below by way of examples.
実施例 本発明における実施例および比較例では、いずれもメ
ルトブロー法により得られたポリエチレンテレフタレー
トの不織布を用いた。血液は、抗凝固剤としてACD液を
用いた新鮮牛血液を使用した。実験は、ヘッド差130cm
の定圧操作で2000mlの処理を行い、白血球除去率、血小
板透過率、遊離ヘモグロビン濃度を測定した。Examples In Examples and Comparative Examples in the present invention, a polyethylene terephthalate nonwoven fabric obtained by a melt blow method was used. The blood used was fresh bovine blood using an ACD solution as an anticoagulant. Experiment, head difference 130cm
2,000 ml of the treatment was performed by the constant pressure operation described above, and the leukocyte removal rate, platelet permeability, and free hemoglobin concentration were measured.
また、不織布極細繊維の糸径は、走査電子顕微鏡によ
り写真撮影し、１種類のサンプルについて50点の計測を
行うことにより決定した。The yarn diameter of the nonwoven fabric ultrafine fiber was determined by taking a photograph with a scanning electron microscope and measuring 50 points of one type of sample.
なお、ポリエチレンテレフタレート繊維の比重として
は1.38g/cm3を用いて繊維間隙の平均円相当直径を算出
した。The average diameter of the fiber gap was calculated using a specific gravity of 1.38 g / cm 3 for the polyethylene terephthalate fiber.
〔実施例１〕 平均糸径3.5μｍの極細繊維不織布を9.0g採取し、フ
ィルター面積41cm2、嵩密度0.20g/cm3に充填した。実施
例で記述した方法に従い、処理温度37℃、処理速度は20
ml/minとなるように調節した。尚、この時の繊維間隙の
平均円相当直径は24μｍであり、血液処理量１当りの
不織布フィルター繊維の表面積は3.7m2であった。結果
は図１に示すように、処理開始初期においては、血小板
透過率は低いが、処理量が500mlを超え、白血球の除去
率が98％以下となった時に血小板透過率がほぼ100％に
達した。白血球の除去率は、75％まで下がった後、一定
値を示し、この傾向は実験終了時（2000ml処理）まで続
いた。遊離ヘモグロビン値は上昇せず、また、操作中目
詰まり等による処理速度の低下も認めなかった。Example 1 9.0 g of an ultrafine fiber nonwoven fabric having an average yarn diameter of 3.5 μm was collected and filled into a filter having a filter area of 41 cm 2 and a bulk density of 0.20 g / cm 3 . According to the method described in the examples, the processing temperature is 37 ° C., and the processing speed is 20
It was adjusted to be ml / min. At this time, the average equivalent circle diameter of the fiber gap was 24 μm, and the surface area of the nonwoven fabric filter fiber per blood treatment amount was 3.7 m 2 . As shown in FIG. 1, the platelet permeability was low at the beginning of treatment, but reached 100% when the treatment volume exceeded 500 ml and the leukocyte removal rate was 98% or less, as shown in FIG. did. The leukocyte removal rate showed a constant value after dropping to 75%, and this tendency continued until the end of the experiment (2000 ml treatment). The free hemoglobin value did not increase, and the processing speed did not decrease due to clogging during operation.
〔実施例２〕 実施例１と同様なモジュールを用い、処理温度のみ20
℃として他の条件は実施例１と同様にして行った。結果
はTable 1に示すように、白血球除去率、血小板透過率
共に良好な性能を示した。Example 2 A module similar to that of Example 1 was used, and only the processing temperature was 20%.
The other conditions were set as in the same manner as in Example 1. As shown in Table 1, the results showed good performance in both leukocyte removal rate and platelet permeability.
〔比較例１〕 実施例１と同様なモジュールを用い、処理温度のみ10
℃とし、他の条件は、実施例１と同様にして行った。結
果はTable 1に示すように、白血球の除去率は上昇した
が血小板の透過率が大きく低下する問題点を示した。[Comparative Example 1] A module similar to that of Example 1 was used.
C., and the other conditions were the same as in Example 1. The results showed that, as shown in Table 1, the leukocyte removal rate increased, but the platelet permeability decreased significantly.
〔比較例２〕 実施例１と同様な極細繊維不織布を嵩密度0.30g/cm3
に充填し、実施例１と同様の条件で実験を行った。結果
はTable 1に示すように血小板透過率が低下する問題点
を示した。なお、この時の繊維間隙の平均円相当直径は
126μｍと狭かった。[Comparative Example 2] A microfiber nonwoven fabric similar to that of Example 1 was applied to a bulk density of 0.30 g / cm 3.
And an experiment was performed under the same conditions as in Example 1. The results showed that the platelet permeability decreased as shown in Table 1. In this case, the average equivalent circle diameter of the fiber gap is
It was as narrow as 126 μm.
〔比較例３〕 実施例１と同様な極細繊維不織布を嵩密度0.11g/cm3
に充填し、実施例１と同様の条件で実験を行った。結果
はTable 1に示すように、白血球の除去率が低下する問
題点を示した。この時の繊維間隙の円相当直径は40.4μ
ｍと広かった。[Comparative Example 3] A microfiber nonwoven fabric similar to that of Example 1 was applied to a bulk density of 0.11 g / cm 3.
And an experiment was performed under the same conditions as in Example 1. The results showed a problem that the leukocyte removal rate was reduced as shown in Table 1. The fiber equivalent diameter of the fiber gap at this time is 40.4μ
m and wide.
〔実施例３〕 平均糸径8.0μｍの極細繊維不織布を18g採取し、フィ
ルター面積41cm2、嵩密度0.40g/cm3に充填し、実施例１
と同様の条件で実験を行った。尚この時の繊維間隙の平
均円相当直径は19.6μｍであり血液処理量１当りの不
織布フィルター繊維の表面積は3.3m2である。結果はTab
le 1に示すように白血球除去率、血小板透過率共に良好
な性能を示した。Example 3 18 g of a microfiber nonwoven fabric having an average yarn diameter of 8.0 μm was collected and filled into a filter having a filter area of 41 cm 2 and a bulk density of 0.40 g / cm 3.
An experiment was performed under the same conditions as described above. At this time, the average fiber equivalent diameter of the fiber gap was 19.6 μm, and the surface area of the nonwoven fabric filter fiber per blood treatment amount was 3.3 m 2 . Result is Tab
As shown in le 1, both leukocyte removal rate and platelet permeability showed good performance.
〔比較例４〕 平均糸径2.0μｍの極細繊維不織布を6.0g採取し、嵩
密度0.15g/cm3に充填し、実施例１と同様の条件で実験
を行った。尚この時の繊維間隙の平均円相当直径は16.4
μｍであり、血液処理量１当りの不織布フィルター繊
維の表面積は4.3m2である。結果はTable 1に示すように
血小板透過率が低下する問題点を示した。[Comparative Example 4] 6.0 g of a microfiber nonwoven fabric having an average yarn diameter of 2.0 µm was collected and filled to a bulk density of 0.15 g / cm 3 , and an experiment was performed under the same conditions as in Example 1. At this time, the average circle equivalent diameter of the fiber gap was 16.4.
μm, and the surface area of the nonwoven fabric filter fiber per blood throughput is 4.3 m 2 . The results showed that the platelet permeability decreased as shown in Table 1.
〔比較例５〕 実験例１と同様な極細繊維不織布を4.0g採取し、嵩密
度0.20g/cm3に充填し、実施例１と同様の条件で実験を
行った。この時の処理血液量１当りの不織布フィルタ
ー繊維の表面積は1.6m2である。結果はTable 1に示すよ
うに白血球除去率が低下する問題点を示した。[Comparative Example 5] 4.0 g of the same ultrafine fiber nonwoven fabric as in Experimental Example 1 was collected and filled to a bulk density of 0.20 g / cm 3 , and an experiment was performed under the same conditions as in Example 1. At this time, the surface area of the nonwoven fabric filter fiber per treated blood volume is 1.6 m 2 . The results showed that the leukocyte removal rate decreased as shown in Table 1.
（発明の効果） 本発明によるとき血液から血小板を大部分透過し、効
率的かつ安全に白血球を除去することができる。 (Effect of the Invention) According to the present invention, platelets can be largely transmitted from blood, and leukocytes can be efficiently and safely removed.
フロントページの続き (58)調査した分野(Int.Cl.6，ＤＢ名) A61M 1/16 500 A61M 1/02 540 A61M 1/36 545 Continuation of the front page (58) Field surveyed (Int.Cl. 6 , DB name) A61M 1/16 500 A61M 1/02 540 A61M 1/36 545
Claims (1)
ルター繊維の表面積が処理血液１当たり2.0〜10.0m2
であって、次式で定義される繊維間隙の平均円相当直径
が16.0〜35.0μｍになるように充填された白血球除去率
が70〜98％、血小板透過率が90％以上である白血球分離
フィルターであることを特徴とする。 DH：繊維間隙の平均円相当直径（μｍ） γ :繊維の平均直径（μｍ） ρ :繊維の密度（g/cm3） γm:フィルターの嵩密度（g/cm3）(1) The average fiber diameter is 3.0 to 8.0 μm, and the surface area of the filter fiber is 2.0 to 10.0 m 2 per treated blood.
And a leukocyte separation filter filled with a leukocyte removal rate of 70 to 98% and a platelet permeability of 90% or more, so that the average equivalent circle diameter of the fiber gap defined by the following formula is 16.0 to 35.0 μm. It is characterized by being. D H : average circle equivalent diameter of fiber gap (μm) γ: average fiber diameter (μm) ρ: fiber density (g / cm 3 ) γm: bulk density of filter (g / cm 3 )
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1110683A JP2893710B2 (en) | 1989-04-27 | 1989-04-27 | Leukocyte separation filter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1110683A JP2893710B2 (en) | 1989-04-27 | 1989-04-27 | Leukocyte separation filter |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02286171A JPH02286171A (en) | 1990-11-26 |
| JP2893710B2 true JP2893710B2 (en) | 1999-05-24 |
Family
ID=14541804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1110683A Expired - Fee Related JP2893710B2 (en) | 1989-04-27 | 1989-04-27 | Leukocyte separation filter |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2893710B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4953295B2 (en) * | 2006-11-24 | 2012-06-13 | 旭化成クラレメディカル株式会社 | Specific cell adsorber |
-
1989
- 1989-04-27 JP JP1110683A patent/JP2893710B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02286171A (en) | 1990-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5679264A (en) | Gas plasma treated porous medium and method of separation using same | |
| EP0811412B1 (en) | Filter medium for leukocyte removal | |
| EP0502213B1 (en) | A method for removing leukocytes and a filter system for removing the same | |
| JP3435494B2 (en) | Leukocyte removal filter and system for leukocyte removal of body fluid | |
| JPH05501368A (en) | Blood processing equipment and blood processing methods for human blood transfusion | |
| JPH0213587B2 (en) | ||
| JP2804055B2 (en) | Preparation method of non-infectious substance containing virus antigen or antibody | |
| JPH0659304B2 (en) | Blood component separation method | |
| JP2893710B2 (en) | Leukocyte separation filter | |
| US6182834B1 (en) | Filter coated with chitosan for removal of leucocytes | |
| JP3250833B2 (en) | Leukocyte selective capture filter material | |
| JPH0624995A (en) | Leukocyte-collecting material | |
| JP2811707B2 (en) | Leukocyte removal fiber and leukocyte removal filter | |
| JP2870796B2 (en) | Leukocyte separation filter in platelet preparation | |
| JP2613249B2 (en) | Leukocyte removal material and leukocyte removal filter | |
| JP2503505B2 (en) | Leukocyte removal filter | |
| JP3419831B2 (en) | Aggregate removal filter in blood and filter device for blood treatment | |
| JPH119923A (en) | Filter medium for removing white corpuscle | |
| JPH1142406A (en) | Leucocyes removing filter medium | |
| JPH09620A (en) | Extracorporeal blood circulating and processing system for treatment of behcet's disease | |
| JPH1112182A (en) | Production of filter material for removing leukocyte, filter material and device using the same and used for removing leukocyte | |
| JP2521090B2 (en) | Blood cell separator | |
| JP3101356B2 (en) | Leukocyte removal filter | |
| JP2004166749A (en) | Method, apparatus and system for recovering leukocyte-removed blood remaining in leukocyte removing filter | |
| JP3467757B2 (en) | Leukocyte removal filter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080305 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090305 Year of fee payment: 10 |
|
| LAPS | Cancellation because of no payment of annual fees |